Diagnostic Innovation Reimagined

Unlocking earlier, more accurate disease detection and monitoring through next-generation sequencing.

The Renew Portfolio

Our Mission

Renew Biotechnologies develops genomic and epigenomic technologies purpose-built for clinical translation—bridging the gap between breakthrough discovery and diagnostic impact.

Learn More
What we do

Rethinking the Approach to Biotech

Identify

We identify the most urgent gaps in healthcare—areas our technologies are uniquely positioned to deliver transformative solutions.

Develop

We engineer impactful precision genomic and epigenomic tools through rigorous R&D—combining scientific innovation with clinical relevance.

Optimize

We optimize every solution for reliability, robustness, and throughput—accelerating the path from proof of concept to clinical and commercial readiness.

Launch

We launch each solution with clear paths to adoption—leveraging the most effective clinical, commercial, and strategic channels to maximize impact.

Our progress

Clinical Development Pipeline

Our pipeline emphasizes clinically actionable biomarkers, scalable assay design, and a clear path to regulatory approval.

Tangible Progress

Portfolio Company Highlight - Resonant

1

Pioneering Early Detection of Neurodegenerative Diseases

Neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS are often diagnosed too late for meaningful intervention. Resonant is developing blood tests for earlier detection and personalized care by identifying DNA biomarkers of dying neurons through cell-of-origin sequencing. 

In collaboration with BYU and the University of Kansas ADRC, this approach is being validated in a 12-year longitudinal study of over 700 individuals.

Learn More